Kobayashi Pharmaceutical Co Ltd
TSE:4967
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (12.1), the stock would be worth ¥4 595.56 (21% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 15.4 | ¥5 842 |
0%
|
| 3-Year Average | 12.1 | ¥4 595.56 |
-21%
|
| 5-Year Average | 15.1 | ¥5 753.31 |
-2%
|
| Industry Average | 8.7 | ¥3 286.92 |
-44%
|
| Country Average | 8.7 | ¥3 290.97 |
-44%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
¥370.2B
|
/ |
Jan 2026
¥23.7B
|
= |
|
|
¥370.2B
|
/ |
Dec 2026
¥24.7B
|
= |
|
|
¥370.2B
|
/ |
Dec 2027
¥28.8B
|
= |
|
|
¥370.2B
|
/ |
Dec 2028
¥33.4B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Kobayashi Pharmaceutical Co Ltd
TSE:4967
|
434.3B JPY | 15.4 | 118.8 | |
| FR |
|
L'Oreal SA
PAR:OR
|
184.2B EUR | 17.1 | 30.1 | |
| UK |
|
Unilever PLC
LSE:ULVR
|
92B GBP | 11.3 | 11.2 | |
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
5.2T INR | 35.8 | 37.2 | |
| UK |
|
HALEON PLC
LSE:HLN
|
31.4B GBP | 13.2 | 18.8 | |
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
27.4B USD | 14.3 | -154.1 | |
| DE |
|
Beiersdorf AG
XETRA:BEI
|
16.4B EUR | 8.2 | 17.4 | |
| JP |
|
Kao Corp
TSE:4452
|
2.7T JPY | 10 | 22.6 | |
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1.1T INR | 37.3 | 62 | |
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD | -6 373.4 | -4 624.4 | |
| IN |
|
Dabur India Ltd
NSE:DABUR
|
783.4B INR | 31.5 | 43.4 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 6.7 |
| Median | 8.7 |
| 70th Percentile | 12.2 |
| Max | 214 699 781.2 |
Other Multiples
Kobayashi Pharmaceutical Co Ltd
Glance View
In the bustling landscape of Japanese business, Kobayashi Pharmaceutical Co., Ltd. stands as an epitome of innovation and tradition. Founded in 1886, this company, steeped in history, has consistently demonstrated a knack for transforming simple consumer needs into thriving business opportunities. Core to its operations is the development, manufacturing, and marketing of consumer healthcare products that subtly blend pharmaceutical expertise with daily convenience. This approach has allowed Kobayashi Pharmaceutical to carve out a distinctive niche, particularly in over-the-counter (OTC) health and personal care products. The company's vast array of products is remarkably diverse, ranging from cooling gel sheets for fevers to herbal medicinal drinks, each crafted with an understanding of consumer pain points and a commitment to well-being. What sets Kobayashi apart in the competitive market is its strategic focus on niche products that serve unmet needs. This laser-sharp business model does more than just bolster its domestic market; it drives its global expansion into key markets in Asia, North America, and Europe. The company's profitability hinges not just on innovation but also on its agile response to the shifting preferences of health-conscious consumers. Driven by a mission to deliver "small but valuable products," Kobayashi’s nimble approach, coupled with an impressive R&D focus, ensures that it remains at the forefront of both consumer satisfaction and shareholder value. Much like a well-crafted Japanese garden, every part of Kobayashi's operation is meticulously designed to function harmoniously, making it a standout player in the global consumer healthcare industry.